Evaluation of Systemic Inflammatory Response and Nutritional Biomarkers as Predictive Factors in Patients with Recurrent Gastric Cancer.
Adult
Aged
Aged, 80 and over
Antigens, Tumor-Associated, Carbohydrate
/ blood
CA-125 Antigen
/ blood
Carcinoembryonic Antigen
/ blood
Female
Humans
Lymphocytes
/ pathology
Male
Middle Aged
Neoplasm Recurrence, Local
/ blood
Neutrophils
/ pathology
Nutrition Assessment
Prognosis
Retrospective Studies
Stomach Neoplasms
/ pathology
Survival Rate
Systemic Inflammatory Response Syndrome
/ diagnosis
Gastric cancer
Glasgow prognostic score
Prognostic value
Recurrence
Survival
Journal
Oncology
ISSN: 1423-0232
Titre abrégé: Oncology
Pays: Switzerland
ID NLM: 0135054
Informations de publication
Date de publication:
2020
2020
Historique:
received:
18
12
2019
accepted:
16
01
2020
pubmed:
18
3
2020
medline:
16
7
2020
entrez:
18
3
2020
Statut:
ppublish
Résumé
The present study sought to evaluate host-related factors as predictors in patients receiving chemotherapy for recurrent advanced gastric cancer. Sixty-three patients were enrolled in the study and received chemotherapy for recurrent gastric cancer at the Kochi Medical School from 2008 to 2015. Clinicopathological information and systemic inflammatory response data were obtained retrospectively to investigate associations between baseline cancer-related prognostic variables and survival outcomes. The median survival time was significantly higher for patients with a Glasgow prognostic score (GPS) of 0 compared to a GPS of 1 or 2 (18.2 vs. 7.1 months; p = 0.006), and for patients in the normal range for carbohydrate antigen-125 (CA125) compared to higher levels (17.9 vs. 4.1 months; p = 0.003). There was no significant influence on overall survival by age, gender, disease status, metastatic site, time to recurrence, carcinoembryonic antigen level, CA19-9 level, prognostic nutrition index, or neutrophil to lymphocyte ratio according to the results of the univariate log-rank tests. Multivariate survival analysis identified a GPS of 1 or 2 (hazard ratio, 3.520; 95% confidence interval, 1.343-9.227; p = 0.010) and a high CA125 level (hazard ratio, 3.135; 95% confidence interval, 1.276-7.697; p = 0.013) as significant independent predictors associated with a poorer prognosis in the studied group of cancer patients. A GPS of 1 or 2 and a high level of CA125 are independent predictors of a poorer prognosis in patients receiving chemotherapy for recurrent gastric cancer.
Sections du résumé
BACKGROUND
BACKGROUND
The present study sought to evaluate host-related factors as predictors in patients receiving chemotherapy for recurrent advanced gastric cancer.
METHODS
METHODS
Sixty-three patients were enrolled in the study and received chemotherapy for recurrent gastric cancer at the Kochi Medical School from 2008 to 2015. Clinicopathological information and systemic inflammatory response data were obtained retrospectively to investigate associations between baseline cancer-related prognostic variables and survival outcomes.
RESULTS
RESULTS
The median survival time was significantly higher for patients with a Glasgow prognostic score (GPS) of 0 compared to a GPS of 1 or 2 (18.2 vs. 7.1 months; p = 0.006), and for patients in the normal range for carbohydrate antigen-125 (CA125) compared to higher levels (17.9 vs. 4.1 months; p = 0.003). There was no significant influence on overall survival by age, gender, disease status, metastatic site, time to recurrence, carcinoembryonic antigen level, CA19-9 level, prognostic nutrition index, or neutrophil to lymphocyte ratio according to the results of the univariate log-rank tests. Multivariate survival analysis identified a GPS of 1 or 2 (hazard ratio, 3.520; 95% confidence interval, 1.343-9.227; p = 0.010) and a high CA125 level (hazard ratio, 3.135; 95% confidence interval, 1.276-7.697; p = 0.013) as significant independent predictors associated with a poorer prognosis in the studied group of cancer patients.
CONCLUSIONS
CONCLUSIONS
A GPS of 1 or 2 and a high level of CA125 are independent predictors of a poorer prognosis in patients receiving chemotherapy for recurrent gastric cancer.
Identifiants
pubmed: 32182616
pii: 000505973
doi: 10.1159/000505973
doi:
Substances chimiques
Antigens, Tumor-Associated, Carbohydrate
0
CA-125 Antigen
0
Carcinoembryonic Antigen
0
carbohydrate antigen 199, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
452-459Informations de copyright
© 2020 S. Karger AG, Basel.